NCT05549024View on ClinicalTrials.gov

68Ga-RM26-RGD PET/CT Imaging in the GRPR and αvβ3 Positive Tumor Patients

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

August 16, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions
Breast CancerProstate CancerBrain TumorPET/CT Imaging
Interventions
DRUG

68Ga-RM26-RGD

Intravenous injection of 68Ga-RM26-RGD with a dosage of approximately 1.8-2.2 MBq (0.05-0.06 mCi)/ kg.

DRUG

18F-FDG

18F-FDG injection

DRUG

68Ga-RM26

Intravenous injection of 68Ga-RM26-RGD with a dosage of approximately 1.8-2.2 MBq (0.05-0.06 mCi)/ kg.

DRUG

68Ga-RGD

Intravenous injection of 68Ga-RGD with a dosage of approximately 1.8-2.2 MBq (0.05-0.06 mCi)/ kg.

Trial Locations (1)

Unknown

RECRUITING

Peking Union Medical College Hospital, Beijing

All Listed Sponsors
lead

Peking Union Medical College Hospital

OTHER